The news: Myosana Therapeutics, a Seattle startup developing gene therapy technology, raised $5 million to develop an early-stage candidate treatment for Duchenne muscular dystrophy (DMD). Mysona says its experimental platform… Read More
Seattle biotech startup Immusoft has received approval to begin clinical trials of its novel strategy for treating genetic disease, the company announced Thursday. Immusoft says it’s the first to get… Read More
Bluebird Bio is growing its nest in Seattle. The leading biotech company held a ribbon-cutting event Friday to celebrate the opening of its new cancer research facility where employees will… Read More
Former Juno Therapeutics executives Hans Bishop and Steve Harr have launched Sana Biotechnology, a startup focused on cell therapy, gene therapy and gene editing. Backed by ARCH Venture Partners, Flagship… Read More
Gene therapy — the process of genetically altering cells to treat disease — is a highly promising process being studied as a way to cure devastating conditions like genetic disorders, HIV,… Read More